12 active not recruiting, 9 completed, 5 terminated, 2 unknown. 17 Phase 2, 7 Phase 1, 3 Not applicable, 2 Early Phase 1, 2 Phase 3.
Follow Stage III Breast Cancer AJCC v7: new trials by email Literature Review of Stage III Breast Cancer AJCC v7 trials Research Report on Stage III Breast Cancer AJCC v7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection Questionnaire Administration, Biospecimen Collection - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Recruiting | Alliance for Clinical Trials in Oncology | 2900 | 2022-08-18 | 2026-10-28 | |
| TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Placebo Administration - Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7 | Phase 2 | Unknown | Academic and Community Cancer Research United | 480 | 2020-02-20 | 2023-12-18 |
| Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy Atorvastatin, Capecitabine - Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2019-09-23 | 2024-10-02 |
| Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence Telemedicine, Best Practice, Questionnaire Administration - Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7 | Not applicable | Completed | Thomas Jefferson University | 305 | 2019-07-31 | 2026-02-05 |
| SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer Implanted Medical Device, Therapeutic Conventional Surgery - Positive Axillary Lymph Node, Stage 0 Breast Cancer AJCC v6 and v7 | Early Phase 1 | Completed | Jonsson Comprehensive Cancer Center | 27 | 2019-04-07 | 2023-01-17 |
| Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer Atezolizumab, Biopsy, Bone Scan - Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Terminated | National Cancer Institute (NCI) | 190 | 2019-04-05 | 2026-05-29 |
| Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors American Ginseng, Laboratory Biomarker Analysis, Placebo - Cancer Survivor, Stage I Breast Cancer AJCC v7 | Early Phase 1 | Completed | Mayo Clinic | 2 | 2019-03-01 | 2023-01-05 |
| Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery Endoxifen Hydrochloride, Placebo Administration, Questionnaire Administration - Breast Carcinoma In Situ, Breast Ductal Carcinoma In Situ | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 32 | 2018-10-31 | 2026-09-02 |
| Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib Neratinib, Trastuzumab, Loperamide - HER2-positive Breast Cancer, Breast Adenocarcinoma | Phase 2 | Completed | University of California, San Francisco | 11 | 2018-10-09 | 2025-06-26 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery Glembatumumab Vedotin, Ipilimumab, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2018-04-20 | 2018-07-18 | |
| Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability Laboratory Biomarker Analysis, Pembrolizumab - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 2 | Active not recruiting | Rutgers, The State University of New Jersey | 21 | 2018-03-08 | 2026-04-03 |
| Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer Cyclophosphamide, Doxorubicin, Laboratory Biomarker Analysis - Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 34 | 2018-02-19 | 2026-02-12 |
| Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis - Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma | Active not recruiting | Mayo Clinic | 68 | 2017-11-13 | 2026-06-09 | |
| Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer Binimetinib, Laboratory Biomarker Analysis, Pembrolizumab - Breast Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 23 | 2017-09-27 | 2025-06-27 |
| Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer Atezolizumab, Biospecimen Collection, Carboplatin - Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 67 | 2017-08-02 | 2026-09-30 |
| Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine - Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 280 | 2017-03-31 | 2026-06-30 |
| Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Biospecimen Collection, Laboratory Biomarker Analysis, Patient Observation - Breast Carcinoma In Situ, Invasive Breast Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1195 | 2017-01-18 | 2026-10-26 |
| Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC Carboplatin, Paclitaxel, Panitumumab - Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7 | Phase 2 | Completed | M.D. Anderson Cancer Center | 43 | 2016-11-03 | 2025-11-06 |
| Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer Axillary Lymph Node Dissection, Enzalutamide, Laboratory Biomarker Analysis - Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7 | Phase 2 | Completed | M.D. Anderson Cancer Center | 24 | 2016-09-22 | 2026-05-12 |
| Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment Electroacupuncture Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 111 | 2016-09-13 | 2026-10-09 |
Showing 20 of 30. Sign in to see all of them.
Breast Neoplasms (30) · Triple Negative Breast Neoplasms (11) · Breast Carcinoma In Situ (4) · Neoplasm Metastasis (4) · Inflammatory Breast Neoplasms (3) · Melanoma (3) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Hematologic Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lung Neoplasms (2) · Prostatic Neoplasms (2) · Sarcoma (2) · Thyroid Neoplasms (2) · Urinary Bladder Neoplasms (2)
Breast Diseases (30) · Neoplasms by Site (30) · Skin Diseases (30) · Skin and Connective Tissue Diseases (30) · Neoplasms (29) · Neoplasms by Histologic Type (8) · Carcinoma (7) · Neoplasms, Glandular and Epithelial (7) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Carcinoma in Situ (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Nerve Tissue (4)
Taxes (7) · Paclitaxel (6) · Trastuzumab (4) · 2C4 antibody (3) · Ogivri (3) · Ontruzant (3) · PF-05280014 (3) · pembrolizumab (3) · pertuzumab (3) · trastuzumab biosimilar HLX02 (3) · Biopsy (2) · Carboplatin (2) · Colony-Stimulating Factors (2) · Cyclophosphamide (2) · Magnetic Resonance Spectroscopy (2)
National Cancer Institute (NCI) (10) · M.D. Anderson Cancer Center (8) · Mayo Clinic (3) · Academic and Community Cancer Research United (2) · Alliance for Clinical Trials in Oncology (1) · City of Hope Medical Center (1) · Jonsson Comprehensive Cancer Center (1) · Rutgers, The State University of New Jersey (1) · Thomas Jefferson University (1) · University of Bergen (1) · University of California, San Francisco (1)
United States (28) · Canada (4) · Norway (1) · Puerto Rico (1)
Clinton Yam (3) · Lorenzo Cohen (2) · Carlos H Barcenas (1) · Charles E Geyer (1) · Ciara O'Sullivan, M.B., B.Ch. (1) · Eugenia Girda, MD (1) · Gini F Fleming (1) · Haeseong Park (1) · Jennifer Baker, MD (1) · Jo Chien, MD (1) · Joseph W Kim (1) · Kathryn J Ruddy (1) · Lajos Pusztai (1) · Marie Wood, MD (1) · Matthew P Goetz (1)
PMID 34253579, PMID 34652548, PMID 35507014, PMID 35914239, PMID 35948919, PMID 37311055, PMID 37505106, PMID 37547448, PMID 38152697, PMID 38484209, PMID 39356138, PMID 39503605, PMID 39558017, PMID 39863139, PMID 39979836, PMID 40170372, PMID 41116969, PMID 41389341, PMID 41499420, PMID 42093035
UM1CA186689 (3), P30CA015083 (2), UM1CA186644 (2), UM1CA186704 (2), N01CN00035 (1), P30CA014599 (1), P30CA016672 (1), P30CA033572 (1), P30CA060553 (1), P30CA072720 (1), P50CA168504 (1), U01CA062505 (1), U01CA069912 (1), U01CA070095 (1), U01CA132123 (1)